Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSI-7904L
- Development stage
- Phase 2
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
OSI-7904L is a liposome-encapsulated formulation of the benzoquinazoline folate analog OSI-7904 with antineoplastic activity. As a thymidylate synthase inhibitor, OSI-7904 noncompetitively binds to thymidylate synthase, resulting in inhibition of thymine nucleotide synthesis and DNA replication. The innovative lipid coating allows for more enduring results with administration of the thymidylate synthase inhibitor. Liposome encapsulation improves the efficacy and increases the half-life of OSI-7904.
- Other names
- osi-7904osi7904osi 7904gw1843u89gw-1843u89gw 1843u89
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on OSI-7904L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSI-7904L.